Akcea Theraps Drug Patent Portfolio
Akcea Theraps owns 1 orange book drug protected by 6 US patents Given below is the list of Akcea Theraps's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8697860 | Diagnosis and treatment of disease | 29 Apr, 2031 | Active |
| US9061044 | Modulation of transthyretin expression | 29 Apr, 2031 | Active |
| US9399774 | Modulation of transthyretin expression | 29 Apr, 2031 | Active |
| US8101743 | Modulation of transthyretin expression | 01 Apr, 2025 | Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines | 05 Sep, 2023 | Expired |
| US7015315 | Gapped oligonucleotides | 21 Mar, 2023 | Expired |
Latest Legal Activities on Akcea Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Akcea Theraps.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US8101743 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jan, 2024 | US9399774 |
|
FDA Final Eligibility Letter
Critical
| 14 Nov, 2023 | US8101743 |
|
FDA Final Eligibility Letter
Critical
| 14 Nov, 2023 | US9061044 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US9061044 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US9399774 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US9061044 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US9399774 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Dec, 2022 | US9061044 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Sep, 2021 | US8697860 |
| Second letter to regulating agency to determine regulatory review period | 17 Aug, 2020 | US8101743 |
| Second letter to regulating agency to determine regulatory review period | 17 Aug, 2020 | US9061044 |
Akcea Theraps's Drug Patent Litigations
Akcea Theraps's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2000, against patent number US7015315. The petitioner , challenged the validity of this patent, with COOK et al as the respondent. Click below to track the latest information on how companies are challenging Akcea Theraps's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7015315 | September, 2004 |
Decision
(27 Apr, 2005)
| COOK et al | |
| US7015315 | October, 2000 |
Decision
(31 Oct, 2002)
| COOK et al | |
Akcea Theraps's Family Patents
Akcea Theraps Drug List
Given below is the complete list of Akcea Theraps's drugs and the patents protecting them.
1. Tegsedi
Tegsedi is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8697860 | Diagnosis and treatment of disease |
29 Apr, 2031
(6 years from now)
| Active |
| US9061044 | Modulation of transthyretin expression |
29 Apr, 2031
(6 years from now)
| Active |
| US9399774 | Modulation of transthyretin expression |
29 Apr, 2031
(6 years from now)
| Active |
| US8101743 | Modulation of transthyretin expression |
01 Apr, 2025
(3 months from now)
| Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines |
05 Sep, 2023
(1 year, 3 months ago)
| Expired |
| US7015315 | Gapped oligonucleotides |
21 Mar, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tegsedi's drug page